X

Trial Profile

A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients With Advanced Leukemias or Myelodysplastic Syndromes

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Plogosertib (Primary) ; Plogosertib (Primary)
Indications Leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man
Sponsors Cyclacel Pharmaceuticals

Most Recent Events

19 Sep 2024 Status changed from recruiting to discontinued.
18 Dec 2023 According to a Cyclacel Pharmaceuticals media release, patients are being recruited at dose level 5. To date, 15 patients have been recruited at five dose escalation levels.
22 Apr 2022 Planned End Date changed from 28 Feb 2021 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com